Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H20N4O8S2 |
Molecular Weight | 532.5492 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 3 / 3 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
c1ccc(cc1)[C@]([H])(C(=N[C@]2([H])C(=O)N3C(=C(C[n+]4ccc(cc4)C(=N)O)CS[C@]23[H])C(=O)O)O)S(=O)(=O)[O-]
InChI
InChIKey=SYLKGLMBLAAGSC-QLVMHMETSA-N
InChI=1S/C22H20N4O8S2/c23-18(27)13-6-8-25(9-7-13)10-14-11-35-21-15(20(29)26(21)16(14)22(30)31)24-19(28)17(36(32,33)34)12-4-2-1-3-5-12/h1-9,15,17,21H,10-11H2,(H4-,23,24,27,28,30,31,32,33,34)/t15-,17-,21-/m1/s1
DescriptionSources: https://www.epharmapedia.com/medicine/profile/156389/Takesulin.html?lang=en&tab=druginfoCurator's Comment:: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/3536385 | http://www.229877.com/article/2013/0126/32350.html
Sources: https://www.epharmapedia.com/medicine/profile/156389/Takesulin.html?lang=en&tab=druginfo
Curator's Comment:: description was created based on several sources, including: https://www.ncbi.nlm.nih.gov/pubmed/3536385 | http://www.229877.com/article/2013/0126/32350.html
Cefsulodin is a third-generation of cephalosporin antibiotic with a narrow spectrum of activity. It has a specific activity against Pseudomonas aeruginosa. Cefsulodin’s targets are bacterial penicillin binding proteins. Drug is indicated for the treatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms. Cefsulodin appears to be well tolerated and relatively free of any significant toxicity except for nausea and vomiting.
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/3757584
Curator's Comment:: Known to be CNS penetrant in rat. Human data not available
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/417670
Curator's Comment:: # Takeda Chemical Industries, Ltd.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Curative | Takesulin Approved UseTreatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms. |
|||
Curative | Takesulin Approved UseTreatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms. |
|||
Curative | Takesulin Approved UseTreatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms. |
|||
Curative | Takesulin Approved UseTreatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms. |
|||
Curative | Takesulin Approved UseTreatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms. |
|||
Curative | Takesulin Approved UseTreatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms. |
|||
Curative | Takesulin Approved UseTreatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms. |
|||
Curative | Takesulin Approved UseTreatment of infections of lower respiratory tract, skin and skin structures, urinary tract, bone and joint; treatment of gynecological infections; treatment of intra-abdominal infections; treatment of septicemia and CNS infections including meningitis caused by susceptible strains of specific microorganisms. |
PubMed
Title | Date | PubMed |
---|---|---|
IgE antibodies for penicillins and cephalosporins in rats. III. Antigenic specificity of rat anti-cephalosporin-OvA IgE sera. | 1981 Jan |
|
Epitope analysis of aztreonam by antiaztreonam monoclonal antibodies and possible consequences in beta-lactams hypersensitivity. | 1992 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.229877.com/article/2013/0126/32350.html
Intramuscular: 0.5-1 g daily in 2-4 divided doses
Intravenous: 0.5-1 g. in severe cases up to 2 g.
Route of Administration:
Other
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/417670
Cefsulodin was an effective bactericidal agent against P. aeruguiosa and S. aureus. An apparent decrease in the number of living bacteria was observed at a concentration of 6.25 ug/ml for P. aerugnosa U 31 and 3.13 ug/ml for S. aureus FDA 209- P.
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
J01DD03
Created by
admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
|
||
|
NCI_THESAURUS |
C357
Created by
admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
|
||
|
WHO-VATC |
QJ01DD03
Created by
admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
SUB07420MIG
Created by
admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
|
PRIMARY | |||
|
CHEMBL1617285
Created by
admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
|
PRIMARY | |||
|
62587-73-9
Created by
admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
|
PRIMARY | |||
|
4390
Created by
admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
|
PRIMARY | |||
|
2190
Created by
admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
|
PRIMARY | RxNorm | ||
|
M3216
Created by
admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
|
PRIMARY | Merck Index | ||
|
DB13499
Created by
admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
|
PRIMARY | |||
|
D002441
Created by
admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
|
PRIMARY | |||
|
656575
Created by
admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
|
PRIMARY | |||
|
OV42LHE42B
Created by
admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
|
PRIMARY | |||
|
C98227
Created by
admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
|
PRIMARY | |||
|
558
Created by
admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
|
PRIMARY | |||
|
CEFSULODIN
Created by
admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
|
PRIMARY | |||
|
62587-73-9
Created by
admin on Sat Jun 26 02:55:53 UTC 2021 , Edited by admin on Sat Jun 26 02:55:53 UTC 2021
|
PRIMARY |
ACTIVE MOIETY